Rapid Generation of High Affinity Protein Sensor Elements
快速生成高亲和力蛋白质传感器元件
基本信息
- 批准号:7569990
- 负责人:
- 金额:$ 18.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAntibodiesArchitectureAreaArtsBacteriophagesBindingBiochemicalBiological AssayBiological ModelsBiosensorBiotechnologyCapillary ElectrophoresisCell surfaceChemicalsChemistryClassificationCollaborationsComplexDataDetectionDevelopmentDevicesDiagnosticDiffusionElementsEnzyme-Linked Immunosorbent AssayEvolutionFoundationsGenerationsGoalsHybridomasImmunoassayIn VitroLabelLaboratoriesLibrariesLigandsMagnetismManualsMembraneMembrane ProteinsMessenger RNAMethodsMicrofluidic MicrochipsMicrofluidicsModelingMolecularMolecular BankMolecular TargetMonoclonal AntibodiesNamesNucleic AcidsPerformanceProcessPropertyProteinsProteomicsPyroxylinReagentRecoveryScreening procedureSeriesSimplexvirusSolidSpecificitySpeedStagingStructureSurfaceSystemTechnologyTestingTimeViralVirusWorkaptamerbasecombinatorialcostimprovedmagnetic beadsmolecular recognitionnew technologynovelpublic health relevancereceptorsensorsuccessvirology
项目摘要
DESCRIPTION (provided by applicant): Effective molecular recognition and highly specific chemical interactions between the receptor (sensor) and ligand (target molecule) determine the performance of biosensors; in other words, the usefulness of a biosensor is governed by the quality of the affinity reagent. The invention of hybridoma monoclonal antibody (mAb) technology opened the paradigm of affinity reagents, and since then, there have been many significant breakthroughs including bacteriophage display, cell-surface display, mRNA display and aptamers to name a few. However, the current technology to obtain affinity reagents for new molecular targets continue to be limited by the high cost, lengthy development time, limited availability, and often inadequate biochemical properties (e.g. affinity, specificity, stability, durability) for many applications. This rings especially true in advanced diagnostic and proteomic applications, where the demand for new reagents far exceeds the rate at which they can be produced.
Aptamers are functional binding molecules composed of nucleic acids which are selected from combinatorial nucleic acid libraries by in vitro selection through a process known as Systematic Evolution of Ligands by EXponential enrichment (SELEX) 1, 2. Unlike traditional reagents (i.e. mAb), aptamers provide a significant advantages as biosensors because they are chemically synthesized, can be evolved for affinity as well as specificity, and they undergo reversible de-naturation, thus making them potentially ideal for field use. However, current methods of SELEX usually require intensive manual labor (8-15 rounds of selection) and time (multiple weeks). Technically, the challenge in isolating high affinity binders originates from multiple factors; first, due to the fact that the starting library contains significantly fewer high affinity binders compared to non- and low-affinity binders, they "out-compete" the high-affinity binders due to mass-action, especially during the crucial, early rounds of selection. Secondly, the non specific binding of the aptamers to the molecular target, the solid support or the separation apparatus degrades the efficiency of molecular partitioning. Finally, using traditional methods of selection, such as affinity columns and nitrocellulose membranes, the partition efficiency in separating the high-affinity binders from non/low-binders is limited, necessitating many rounds of selection. Thus, in order to accelerate the affinity reagent generation, a fundamentally new technology platform to screen molecular libraries must be developed that can overcome these key challenges.
Toward this end, our laboratory recently developed a novel system for high performance magnetophoretic separation called CMACS where we use micropatterned ferromagnetic materials in microfluidic channels to generate a highly controlled magnetophoretic force field that separates superparamagnetically labeled molecules from complex backgrounds with unprecedented efficiency. This device allows the use of very small number of magnetic beads (< 106 per selection) and target proteins (down to ~ 20 attomoles) enabling exceptional stringency such that low-affinity binders, do not "out-compete" the high-affinity binders due to mass-action. Furthermore, the partition efficiency (PE) of CMACS to be 1-2 orders of magnitude higher than those achieved by capillary electrophoresis (CE). These advantages, combined with our bead conjugation chemistry, which inhibits non-specific binding have enabled us to generate aptamers with low nanomolar affinities to protein targets, in a single round of selection within 30 minutes of separation. Building on these foundations, the main goal of this work is to: 1) optimize the M-SELEX process and verify that affinities of the aptamers can be further improved with more rounds of selection, and 2) test the generalizability of the M-SELEX system by generating aptamers for multiple protein targets. The success of this project will have significant impact in multiple areas of biotechnology because it will enable the generation of high performance affinity reagents at an unprecedented speed with minimal labor and cost. PUBLIC HEALTH RELEVANCE Detection of target viruses with traditional surface marker-based immunoassays (i.e., ELISA) using monoclonal antibodies (mAb) suffer from major drawbacks because 1) a new mAb typically takes more than 6 months to generate, 2) many of the antibodies cross-react across species and subtypes, thereby compromising the detection specificity, and 3) it is extremely costly to develop arrays of antibodies that can provide a composite signature of the surface proteins. Aptamers are functional binding molecules composed of nucleic acids which are selected from combinatorial libraries by in vitro selection. Unlike mAbs, aptamers provide a significant advantages as biosensors because they are chemically synthesized, can be evolved for affinity as well as specificity, and they undergo reversible de-naturation, thus making them ideal for field use. Expanding on our previous work on ultrahigh performance Microfluidic-SELEX, this proposal seeks to develop the Microfluidic Viral SELEX (MVX) technology which will be capable of generating a set of high affinity aptamers which are specific to the target virus, so that a composite signature of viral surface proteins can be generated on demand - rapidly, efficiently, reproducibly, and in disposable microfluidic devices. We envision that, when fully developed, the proposed MVX technology will be applicable to almost all viruses. However, in this R21 project, in close collaboration with a leading virology lab at UCLA, we propose to use two closely related herpes simplex viruses (HSV) as a model system. HSVs have complex surface structures and they will serve as a challenging, yet realistic models. If successful, the proposed MVX technology has the potential to fundamentally revolutionize the way we generate affinity ligands, and perform viral diagnostics.
描述(由申请人提供):受体(传感器)和配体(靶分子)之间有效的分子识别和高度特异性的化学相互作用决定了生物传感器的性能;换句话说,生物传感器的有用性是由亲和试剂的质量决定的。杂交瘤单克隆抗体(mAb)技术的发明开启了亲和试剂的范式,此后,噬菌体展示、细胞表面展示、mRNA展示和适体等方面取得了许多重大突破。然而,目前获得用于新分子靶点的亲和试剂的技术仍然受到成本高、开发时间长、可用性有限以及许多应用的生化性能(例如亲和性、特异性、稳定性、耐久性)不足的限制。在高级诊断和蛋白质组学应用中尤其如此,在这些应用中,对新试剂的需求远远超过了它们的生产速度。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Generation of highly specific aptamers via micromagnetic selection.
- DOI:10.1021/ac900759k
- 发表时间:2009-07-01
- 期刊:
- 影响因子:7.4
- 作者:Qian, Jiangrong;Lou, Xinhui;Zhang, Yanting;Xiao, Yi;Soh, H. Tom
- 通讯作者:Soh, H. Tom
Multitarget dielectrophoresis activated cell sorter.
- DOI:10.1021/ac8015938
- 发表时间:2008-11-15
- 期刊:
- 影响因子:7.4
- 作者:Kim, Unyoung;Qian, Jiangrong;Kenrick, Sophia A.;Daugherty, Patrick S.;Soh, H. Tom
- 通讯作者:Soh, H. Tom
Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic, electrochemical aptamer-based sensor.
- DOI:10.1021/ja806531z
- 发表时间:2009-04-01
- 期刊:
- 影响因子:15
- 作者:Swensen, James S.;Xiao, Yi;Ferguson, Brian S.;Lubin, Arica A.;Lai, Rebecca Y.;Heeger, Alan J.;Plaxco, Kevin W.;Soh, H. Tom.
- 通讯作者:Soh, H. Tom.
Fluorescence detection of single-nucleotide polymorphisms with a single, self-complementary, triple-stem DNA probe.
- DOI:10.1002/anie.200900369
- 发表时间:2009
- 期刊:
- 影响因子:16.6
- 作者:Xiao, Yi;Plakos, Kory J. I.;Lou, Xinhui;White, Ryan J.;Qian, Jiangrong;Plaxco, Kevin W.;Soh, H. Tom
- 通讯作者:Soh, H. Tom
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HYONGSOK Tom SOH其他文献
HYONGSOK Tom SOH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HYONGSOK Tom SOH', 18)}}的其他基金
Real-time biosensor for mapping the function of the pancreas
用于绘制胰腺功能的实时生物传感器
- 批准号:
9926632 - 财政年份:2019
- 资助金额:
$ 18.39万 - 项目类别:
Real-time biosensor for mapping the function of the pancreas
用于绘制胰腺功能的实时生物传感器
- 批准号:
10455342 - 财政年份:2018
- 资助金额:
$ 18.39万 - 项目类别:
Real-time biosensor for mapping the function of the pancreas
用于绘制胰腺功能的实时生物传感器
- 批准号:
10170068 - 财政年份:2018
- 资助金额:
$ 18.39万 - 项目类别:
Micromagnetic Aptamer PCR System for Ultrasensitive Multiplexed Protein Detection
用于超灵敏多重蛋白质检测的微磁适体 PCR 系统
- 批准号:
7812154 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Strain Specific Detection of Influenza at the Point-of-Care
在护理点对流感病毒株进行特异性检测
- 批准号:
8272670 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Strain Specific Detection of Influenza at the Point-of-Care
在护理点对流感病毒株进行特异性检测
- 批准号:
8070475 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Strain Specific Detection of Influenza at the Point-of-Care
在护理点对流感病毒株进行特异性检测
- 批准号:
7917202 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Strain Specific Detection of Influenza at the Point-of-Care
在护理点对流感病毒株进行特异性检测
- 批准号:
7700189 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Micromagnetic Aptamer PCR System for Ultrasensitive Multiplexed Protein Detection
用于超灵敏多重蛋白质检测的微磁适体 PCR 系统
- 批准号:
7641885 - 财政年份:2009
- 资助金额:
$ 18.39万 - 项目类别:
Rapid Generation of High Affinity Protein Sensor Elements
快速生成高亲和力蛋白质传感器元件
- 批准号:
7472611 - 财政年份:2008
- 资助金额:
$ 18.39万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 18.39万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 18.39万 - 项目类别: